

Summary of Safety and Effectiveness

NOV 26 2002

General Provisions

Trade Name: Renegade STC™ 18 Microcatheter

Classification Name: Diagnostic Intravascular Catheter

Name of Predicate Devices

Renegade™ Hi-Flo Microcatheter, Renegade™ Fiber Braided Microcatheter, Excelsior™ 1018 Microcatheter and Tracker® Excel™ 14

Classification

Class II

Performance Standards

Performance Standards have not been established by FDA under Section 514 of the Food, Drug and Cosmetic Act

Intended Use and Device Description

The Renegade STC™ 18 is intended for general intravascular use, including neuro, peripheral and coronary vasculature. The catheter can be coaxially tracked over a steerable guidewire in order to access distal, tortuous vasculature. Once the subselective region has been accessed, the catheter can be used for controlled and selective infusion of diagnostic, embolic, or therapeutic materials into vessels. The Renegade™ STC-18 Microcatheter is a sterile, single-use catheter and is available in lengths of 105 cm, 130 cm, and 150cm.

Biocompatibility

The Renegade STC-18™ Microcatheter has been tested for biocompatibility per ISO 10993. All data demonstrate this device is biocompatible for its intended use.

Summary of Substantial Equivalence

The Renegade STC™ 18 Microcatheter has been tested and compared to the predicate device. All data gathered demonstrate this device as substantially equivalent. No new issues of safety or efficacy have been raised.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

NOV 26 2002

Boston Scientific Corporation
Ms. Christine M. Cameron
Regulatory Affairs Specialist
One Boston Scientific Place
Natick, MA 01760-1537

Re: K023681
Renegade STC™ 18 Microcatheter
Regulation Number: 21 CFR 870.1200
Regulation Name: Diagnostic intravascular catheter.
Regulatory Class: II
Product Code: DQO
Dated: October 31, 2002
Received: November 1, 2002

Dear Ms. Cameron:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

Page 2 – Ms. Christine M. Cameron

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



Brian D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications For Use

510(k)
Number
(if known)

Unknown
K023681

Device Name: Renegade STC™ 18 Microcatheter

Indications
for Use

The Renegade STC™ 18 Microcatheter is intended for general intravascular use, including neuro, peripheral and coronary vasculature. The catheter can be coaxially tracked over a steerable guidewire in order to access distal, tortuous vasculature. Once the subselective region has been accessed, the catheter can be used for controlled and selective infusion of diagnostic, embolic, or therapeutic materials into vessels.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division of Cardiovascular & Respiratory Devices
510(k) Number K023681

Prescription Use

OR

Over-The Counter Use